Compounds > 3-(2-phenylethyl)-4-methylsydnone
Page last updated: 2024-12-10

3-(2-phenylethyl)-4-methylsydnone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3-(2-phenylethyl)-4-methylsydnone: cytochrome P-450 antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3082702
MeSH IDM0160194

Synonyms (8)

Synonym
114886-35-0
3-(2-phenylethyl)-4-methylsydnone
sydnone, 4-methyl-3-(2-phenylethyl)-
pems
BUCXEFZXWKUCCY-UHFFFAOYSA-N
4-methyl-3-(2-phenylethyl)-1,2,4-oxadiazol-5(4h)-one
DTXSID00921529
4-methyl-3-(2-phenylethyl)-1,2,4-oxadiazol-5-one
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (14.29)18.7374
1990's1 (14.29)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's5 (71.43)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.37

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.37 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.37)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (14.29%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (85.71%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
formaldehyde
paraform: polymerized formaldehyde; RN given refers to parent cpd; used in root canal therapy		2.610aldehyde;
one-carbon compound		allergen;
carcinogenic agent;
disinfectant;
EC 3.5.1.4 (amidase) inhibitor;
environmental contaminant;
Escherichia coli metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
protoporphyrin ix
protoporphyrin IX: RN given refers to parent cpd; structure in Merck Index, 9th ed, #7685. protoporphyrin : A cyclic tetrapyrrole that consists of porphyrin bearing four methyl substituents at positions 3, 8, 13 and 17, two vinyl substituents at positions 7 and 12 and two 2-carboxyethyl substituents at positions 2 and 18. The parent of the class of protoporphyrins.		1.9710
3-(2-(2,4,6-trimethylphenyl)thioethyl)-4-methylsydnone
3-(2-(2,4,6-trimethylphenyl)thioethyl)-4-methylsydnone: porphyrinogenic agent; structure given in first source		1.9710
nadp
[no description available]		1.9710
oxadiazoles
Oxadiazoles: Compounds containing five-membered heteroaromatic rings containing two carbons, two nitrogens, and one oxygen atom which exist in various regioisomeric forms.		2.3820
heme
Heme: The color-furnishing portion of hemoglobin. It is found free in tissues and as the prosthetic group in many hemeproteins.. ferroheme : Any iron(II)--porphyrin coordination complex.. ferroheme b : Heme b in which the iron has oxidation state +2.. heme : A heme is any tetrapyrrolic chelate of iron.		7.3820
ConditionIndicatedRelationship StrengthStudiesTrials
Adolescent Obesity
[description not available]		02.610
Orphan Diseases
Rare diseases that have not been well studied.		03.5210
Carbohydrate-Deficient Glycoprotein Syndrome
[description not available]		03.5210
Congenital Disorders of Glycosylation
A genetically heterogeneous group of heritable disorders resulting from defects in protein N-glycosylation.		03.5210